CIBC Asset Management Inc Boosts Position in IDEXX Laboratories, Inc. $IDXX

CIBC Asset Management Inc increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,818 shares of the company’s stock after purchasing an additional 8,274 shares during the quarter. CIBC Asset Management Inc’s holdings in IDEXX Laboratories were worth $25,585,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its stake in IDEXX Laboratories by 16.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 831,911 shares of the company’s stock valued at $562,813,000 after buying an additional 119,969 shares during the last quarter. Bridges Investment Management Inc. lifted its stake in IDEXX Laboratories by 36.6% in the fourth quarter. Bridges Investment Management Inc. now owns 541 shares of the company’s stock valued at $366,000 after buying an additional 145 shares during the last quarter. Dynasty Wealth Management LLC purchased a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $237,000. Natixis Advisors LLC lifted its stake in IDEXX Laboratories by 66.0% in the fourth quarter. Natixis Advisors LLC now owns 76,773 shares of the company’s stock valued at $51,939,000 after buying an additional 30,528 shares during the last quarter. Finally, 3Chopt Investment Partners LLC purchased a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $204,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on IDXX shares. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Citigroup initiated coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Piper Sandler cut their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Trading Up 1.8%

Shares of IDXX stock opened at $560.73 on Thursday. The business’s fifty day moving average price is $563.43 and its 200 day moving average price is $633.51. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98. The firm has a market capitalization of $44.23 billion, a PE ratio of 41.29, a P/E/G ratio of 3.20 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the company posted $2.91 earnings per share. IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.